Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Dr. Aiguader 88, Barcelona, 08003, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Br J Cancer. 2020 Feb;122(3):315-328. doi: 10.1038/s41416-019-0615-2. Epub 2019 Nov 11.
Polycomb repressive complex 2 (PRC2) is a key epigenetic multiprotein complex involved in the regulation of gene expression in metazoans. PRC2 is formed by a tetrameric core that endows the complex with histone methyltransferase activity, allowing it to mono-, di- and tri-methylate histone H3 on lysine 27 (H3K27me1/2/3); H3K27me3 is a hallmark of facultative heterochromatin. The core complex of PRC2 is bound by several associated factors that are responsible for modulating its targeting specificity and enzymatic activity. Depletion and/or mutation of the subunits of this complex can result in severe developmental defects, or even lethality. Furthermore, mutations of these proteins in somatic cells can be drivers of tumorigenesis, by altering the transcriptional regulation of key tumour suppressors or oncogenes. In this review, we present the latest results from structural studies that have characterised PRC2 composition and function. We compare this information with data and literature for both gain-of function and loss-of-function missense mutations in cancers to provide an overview of the impact of these mutations on PRC2 activity.
多梳抑制复合物 2(PRC2)是一种关键的表观遗传多蛋白复合物,参与后生动物基因表达的调控。PRC2 由一个四聚体核心组成,赋予复合物组蛋白甲基转移酶活性,使其能够单、二和三甲基化组蛋白 H3 赖氨酸 27(H3K27me1/2/3);H3K27me3 是组成性异染色质的标志。PRC2 的核心复合物结合有几个相关因子,这些因子负责调节其靶向特异性和酶活性。该复合物亚基的耗竭和/或突变可导致严重的发育缺陷,甚至致死。此外,这些蛋白质在体细胞中的突变可以通过改变关键肿瘤抑制因子或癌基因的转录调控成为肿瘤发生的驱动因素。在这篇综述中,我们介绍了结构研究的最新结果,这些结果描述了 PRC2 的组成和功能。我们将这些信息与癌症中获得功能和丧失功能的错义突变的数据和文献进行了比较,以概述这些突变对 PRC2 活性的影响。